Patients 18 years of age and older with cystic fibrosis now have an option of participating in a Phase 1 trial of a novel, broad-spectrum, orally delivered enzyme replacement therapy for cystic fibrosis (CF). The randomized, active-treatment trial is testing the safety, tolerability and effect of four dose levels of ANG003, a compound developed by…
Norton Cancer Institute is enrolling metastatic lung cancer patients in a Phase 3 clinical trial to test a promising new anti-CLTA-4 antibody, gotistobart (ONC-392). The study will test whether gotistobart is more effective than the chemotherapy agent docetaxel in prolonging life in patients with metastatic, non-small cell lung cancer whose disease progressed on anti-PD-1/PD-L1 antibody…
Louisville Business First has recognized researchers at Norton Healthcare with its 2024 Health Care Heroes Innovator Award. The award honors those who break ground in the health care field by developing or implementing new technology, treatments or programs with wide applications. Award recipients were: Manager Award This award honors leaders ranging from the head of a small…
Recently approved Tzield (teplizumab-mzwv), is delivering breakthrough results that suggest it may delay the onset of Stage 3 Type 1 diabetes by an average of two years. The first-in-class drug is approved for adults and children ages 8 and older with Stage 2 Type 1 diabetes. “Delaying the onset of Stage 3 not only postpones…
Afrezza inhaled insulin, currently approved for adults, is being tested for children in a clinical trial at Wendy Novak Diabetes Institute, a part of Norton Children’s Endocrinology, affiliated with the UofL School of Medicine. Norton Children’s is one of 40 sites nationally participating in the Phase 3 trial. Afrezza is an ultra-fast-acting inhaled mealtime insulin,…
Researchers are recruiting pediatric medulloblastoma patients for a novel use of difluoromethylornithine (DFMO) to prevent relapse. The multisite study, sponsored by the Beat Childhood Cancer Consortium and led by Michael Angelo C. Huang, M.D., pediatric neuro-oncologist at Norton Children’s Cancer Institute, affiliated with the UofL School of Medicine, looks at whether DFMO offers a new…
Butyrate-producing gut bacteria are a promising target for preventing and treating memory loss associated with Alzheimer’s disease, according to research presented recently at the Alzheimer’s Association International Conference (AAIC) in Amsterdam, Netherlands. The research in 3XTg mouse model demonstrated that oral administration of tributyrin mitigates age-associated loss of butyrate-producing bacteria and prevents the decline in…
Surgeons face two choices for infants with critical left heart obstruction who have had prior hybrid palliation: a Norwood operation or a comprehensive stage II (COMPSII). The critical left heart obstruction cohort of the multi-institutional Congenital Heart Surgeons’ Society looked at patient characteristics and outcomes for these two pathways. The study, “Norwood Operation Versus Comprehensive…
A human Phase 1 immunotherapy clinical trial is underway using natural killer cells, or NK cells, to target relapsed or refractory acute myeloid leukemia. Acute myeloid leukemia patients who have exhausted other treatment options are potential candidates for the trial, ClinicalTrials.gov ID NCT05470140. The trial uses cytokine-reprogrammed, non-engineered, “off-the-shelf” NK cells from a healthy donor….
Norton Cancer Institute is the only site in Louisville offering lutetium Lu 177 dotatate (Lutathera), a second-line treatment targeting advanced-stage neuroendocrine tumors in adult patients. The drug is indicated when a patient starts to lose response to the first-line therapies, lanreotide (Somatuline) and octreotide acetate (Sandostatin). Norton Cancer Institute To refer a patient to Norton…
Researchers at the Norton Healthcare Brain Tumor Center are conducting a clinical trial to determine whether a promising new immunotherapy drug, SurVaxM, improves survivability of glioblastoma. SurVaxM targets survivin, a protein in 95% of glioblastomas and many other cancers. The immunotherapeutic is designed to trigger the patient’s immune system to attack cancer cells with survivin….
A new regimen of FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib and venetoclax was tolerable at standard doses and produced high response rates for advanced, FLT3-mutated acute myeloid leukemia (AML) in a multicenter Phase 1 study. “The results were encouraging. We saw high rates of marrow response and promising overall survival for this high-risk group…